GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma

NARecruitingINTERVENTIONAL

Enrollment

146

Participants

Timeline

Start Date

January 15, 2022

Primary Completion Date

May 15, 2024

Study Completion Date

January 15, 2026

Conditions

Cholangiocarcinoma

Interventions

DRUG

GEMOX Regimen

Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W

DRUG

Lenvatinib

8/12mg PO QD continuously

DRUG

Toripalimab

240mg IV d1 Q3W

Trial Locations (1)

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER